Summary

Market Overview The global sternal closure systems market size was valued at US$ 2,295.25 Million in 2022 and is estimated to reach US$ 3,446.26 Million by 2030, growing at a CAGR of 5.3% during the forecast period (2023-2030). Sternal closure systems refer to medical devices used to close the sternum (breastbone) after a median sternotomy, a surgical procedure in which the sternum is split open for access to the thorax. These systems usually consist of metallic plates, wires, or sutures used to fasten the separated halves of the sternum securely. The goal of sternal closure systems is to provide stability and support to the sternum during the healing process to prevent complications such as infection, wound separation, or instability of the chest. Market DynamicsThe global sternal closure systems market growth is driven by technological advancements increasing incidence of cardiac and thoracic surgeries, growing awareness about the importance of sternal closure, aging population, and rise in healthcare expenditure. An increasing burden of cardiac disorders drives the market growth The growing number of cardiac surgeries, such as coronary artery bypass grafting and valve replacements, drives the demand for sternal closure systems. Across the world, cardiovascular disease (CVD) is the leading cause of mortality. Cardiovascular diseases, principally ischemic heart disease (IHD) and stroke, are major contributors to disability. Because of the high prevalence, mortality, morbidity, and financial burden of treating heart failure (HF), it is a significant healthcare concern. It is anticipated that more than eight million Americans will have HF by 2030. From about 20 per 1,000 people aged 65 to 69 to more than 80 per 1,000 people aged 85 and older, the frequency of HF rises with age. The most frequent causes of HF are valvular heart disease, hypertension, and ischaemic heart disease.In addition, Rheumatic heart disease (RHD) is still a leading etiologic factor in the development of VHD worldwide. In contrast, degenerative valve disease is likely the most common etiology of VHD in developed countries. The prevalence of VHD increases from 0.7 % in people<45 years to 13 % in people over 75 years. Moreover, CVD affects 50% of the world’s population (women). Despite significant progress in cardiovascular care over the past several decades, in 2021, CVD remains the major cause of morbidity and mortality for women. Urbanization and lifestyle modifications are contributing to a rise in the incidence and prevalence of cardiovascular diseases (CVDs) across several African nations, including Ethiopia, as Africans experience a rapid epidemiological transformation.The risk associated with sternal closure systems will hamper the growth of the market However, the risks associated with sternal closure systems. Sternal closure systems can increase the risk of postoperative infections, particularly if the incision is not properly cared for. There is a risk of sternal instability, which can cause the chest bones to separate and lead to pain, difficulty breathing, and other complications. There is a risk of nerve damage during the procedure, which can result in numbness, tingling, or weakness in the chest or arms. There is a risk of the device malfunction, which can lead to broken wires or other issues that require revision surgery. There is a risk of allergic reactions to the materials used in the sternal closure system, such as metals or adhesives.COVID-19 Impact AnalysisThe COVID-19 pandemic has profound adverse effects on the sternal closure systems market. As per the article published in the International Journal of Surgery in 2020, cardiothoracic practice will be inevitably affected by COVID-19. All elective and non-urgent procedures have been postponed in the UK and the US, with resources being redirected to the emergency and urgent cardiothoracic service. Furthermore, cardiothoracic surgeons possess generic skills which are mostly transferable to ITU, making them prime candidates for redeployment. NHS England has issued guidance on managing cardiothoracic procedures based on the phase of the COVID-19 pandemic.The elective cardiothoracic surgery service will be greatly reduced throughout the pandemic. Surgeons are encouraged to use telephone and video conferencing to limit face-to-face appointments and to delay non-urgent referrals and follow-ups. Cardiothoracic surgeons can greatly support the ITU service, and attempts should be made to make senior staff available for redeployment.As of 2023, the COVID-19 situation is recovering, and all patients can access healthcare facilities. In addition, increasing demand for cardiac and thoracic surgeries drives the market worldwide. Segment AnalysisThe closure devices segment is expected to grow at the fastest CAGR during the forecast period (2023-2030) The closure devices segment accounts for the highest market share. Sternal closure devices are used in cardiac surgery to securely close the sternum after a median sternotomy (an incision made down the center of the breastbone). The devices are designed to reduce the time required for sternal healing, minimize wound complications, and reduce patient discomfort compared to traditional wire cerclage methods. There has been increasing demand for sternal closure devices in recent years due to their benefits and technological advancements. Cardiac surgery procedures are becoming more prevalent due to an aging population and advancements in medical technology, leading to a growing demand for reliable and efficient sternal closure methods. Additionally, the benefits of faster recovery time and reduced patient discomfort associated with sternal closure devices have increased demand among patients and healthcare providers.In addition, Medicon offers a titanium sternal closure system that allows stable internal fixation of the sternum after sternotomy or sternal fracture. Different titanium plates are available to suit the anatomical structures and individual clinical requirements. Also, Arthrex, Inc. offers A 100% nonmetallic, suture-based alternative to the conventional use of metal wires to bind the sternum after heart surgery, the FiberTape sternal closure system. Strong, repeatable compression from the FiberTape sternal closure implant, which is placed similarly to metal wires, aids in sternal approximation and stabilization.Geographical AnalysisNorth America region holds the largest market share of the global sternal closure systems market North America dominates the market for sternal closure systems and is expected to show a similar trend over the forecast period. Technological advancements, the rising prevalence of cardiac disease, and product launches by market players in the North American region drive the market. As per the article published in the Journal of Thoracic Disease in 2022, In the U.S., thoracic surgeons can complete their training through various extremely competitive programs and are prepared to manage patients with chest problems during surgery and in the immediate aftermath. An average of 135 procedures are carried out by thoracic surgeons each year to treat conditions affecting the lungs, trachea, esophagus, chest wall, mediastinum, and diaphragm. The most frequent surgeries, usually done to treat lung cancer, are thoracoscopic surgeries with video assistance. With over 200,000 new cases anticipated this year, lung cancer is the deadliest and the second most common cancer in the U.S.Additionally, the University of Michigan Medicine performs about 2,000 adult cardiac surgery procedures yearly using improving and cutting-edge therapies for heart and aortic illnesses.Competitive Landscape The sternal closure systems market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Depuy Synthes (Johnson & Johnson), Zimmer Biomet Holdings, KLS Martin Group, Acute Innovations, JACE Medical, LLC., Stryker, Idear S.R.L, Praesidia SRL, Kinamed Incorporated, and B. Braun, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the sternal closure systems market globally. For instance, • In December 2020, Zimmer Biomet Holdings, Inc., acquired the Stryker Corporation, a Vance Street Capital Portfolio Company, for $150 million in cash at closing and $100 million in cash payable in 2021. Zimmer Biomet has acquired Stryker and its complete product portfolio of sternal closure devices – including cable systems, sternal sutures, and rigid fixation – along with a range of single-use complimentary temporary pacing wire and surgical punch products.Zimmer Biomet Holdings Overview: Zimmer Biomet is a medical device company founded in 1927 and headquartered in the U.S. Their innovations enable the treatment of disorders of, or injuries to, joints, bones, and supporting soft tissues. Together with healthcare professionals, a company helps millions of people to live better lives. Product Portfolio:SternaLock XP Rigid Fixation System: The SternaLock XP Sternal Closure System is implied for stabilizing and fixing fractures of the anterior chest wall for sternal reconstructive procedures for patients with normal and poor bone. The global sternal closure systems market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

ページTOPに戻る

Table of Contents